<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525758</url>
  </required_header>
  <id_info>
    <org_study_id>SI000413_OA_Ⅱ</org_study_id>
    <nct_id>NCT01525758</nct_id>
  </id_info>
  <brief_title>Study of SI000413 in Knee Osteoarthritis Patients</brief_title>
  <official_title>Eight-week, Multi-centre, Dose-response, Double Blind, Placebo-controlled, Randomized, Parallel-group, PhaseⅡ Trial to Evaluate Efficacy and Safety of SI000413 in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of SI000413 in patients with&#xD;
      knee osteoarthritis by orally administration and to determine optimal dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-response, double blind , placebo-controlled study. All patients are required&#xD;
      to have 2 weeks washout period from prior medication. Subjects will discontinue current&#xD;
      medications 2 weeks prior to randomization. Among those who meet the inclusion criteria, only&#xD;
      subjects recording visual analogue scale(VAS) of higher than 40mm(VAS range from 0mm(no pain)&#xD;
      to 100mm(unbearable pain)) are enrolled in this study.&#xD;
&#xD;
      Subjects meeting screening criteria will be randomized to receive 8 weeks dosing of an active&#xD;
      dose of SI000413 or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>K-WOMAC</measure>
    <time_frame>Visit 6(8 week), baseline</time_frame>
    <description>The primary endpoint will be the change in the sum of the K-WOMAC OA index at Visit 6(8 weeks) vs. baseline(Visit 2, 0 week).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>knee pain intensity assessment</measure>
    <time_frame>baseline, Visit 4(4 week), Visit 6(8 week)</time_frame>
    <description>The change from baseline to each day(4 week and 8 week). Subjects assess knee pain intensity by using 100mm VAS at each time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment(regarding to disease activity)</measure>
    <time_frame>Visit 4(4 week), Visit 6(8 week)</time_frame>
    <description>The change from Visit 4 to Visit 6 using 100mm VAS. Each patient and investigator assess by using 100mm VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K-WOMAC each domain assessment</measure>
    <time_frame>baseline, Visit 6(8 week)</time_frame>
    <description>The change from Visit 6(8 weeks) vs. baseline(Visit 2, 0 week) in the K-WOMAC each domain score.&#xD;
* K-WOMAC 3 domains: pain domain, stiffness domain, physical function domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESR &amp; hs-CRP</measure>
    <time_frame>baseline, Visit 4(4 week), Visit 6(8 week)</time_frame>
    <description>The change from baseline to each day(Visit 4, Visit 6) using laboratory test.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>SI000413 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet, SI000413 200mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SI000413 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet, SI000413 200mg tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SI000413 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SI000413 200mg, 2T bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 2T tid for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SI000413</intervention_name>
    <description>1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks</description>
    <arm_group_label>SI000413 400mg</arm_group_label>
    <arm_group_label>SI000413 600mg</arm_group_label>
    <arm_group_label>SI000413 800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>microcrystalline cellulose</intervention_name>
    <description>identical number of tablets to active drug groups</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>SI000413 placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females, 35-75 years old&#xD;
&#xD;
          2. Subjects must have a clinical or radiographic diagnosis of primary OA of the knee&#xD;
             (diagnosed according to the ACR)&#xD;
&#xD;
               -  The presence of knee pain&#xD;
&#xD;
               -  At least one of the following&#xD;
&#xD;
                    -  age older than 50 years&#xD;
&#xD;
                    -  morning stiffness lasting less than 30 minutes&#xD;
&#xD;
                    -  crepitus with motion&#xD;
&#xD;
          3. Subjects must have been symptomatic for at least 3 months prior to enrollment.&#xD;
&#xD;
          4. Subjects must be required to have experienced a pain intensity of at least 40mm on a&#xD;
             100-mm visual analogue scale in the most severely affected joint during the 24 hours&#xD;
             prior to randomization.&#xD;
&#xD;
          5. Adequate liver and kidney function&#xD;
&#xD;
               -  Adequate liver function : SGOT, SGPT must be within 1.5 x normal limit&#xD;
&#xD;
               -  Adequate kidney function : Serum creatinine must be within 1.5 x normal limit&#xD;
&#xD;
          6. Subjects must be able to read, understand and follow the study instructions&#xD;
&#xD;
          7. Subjects must agree to informed consent spontaneously.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are not using adequate birth control.&#xD;
&#xD;
          2. Pregnant or breast-feeding.&#xD;
&#xD;
          3. Subjects requiring Knee surgery within 1 year of screening anticipating any need for a&#xD;
             surgical procedure during the study.&#xD;
&#xD;
          4. Secondary OA patients&#xD;
&#xD;
          5. Similar OA patients(ex. rheumatic arthritis, bursitis etc)&#xD;
&#xD;
          6. Treatment with intra-articular injections of systemic corticosteroids or hyaluronic&#xD;
             acid in the prior 3 months.&#xD;
&#xD;
          7. Use of drugs or psychotropic medicine(methadone maintenance program, codeine, tramadol&#xD;
             hydrochloride)&#xD;
&#xD;
          8. Anemia or coagulant disorder&#xD;
&#xD;
          9. Use of anticoagulants or lithium&#xD;
&#xD;
         10. Use of misoprostol or H2-blocker(including anti ulcer medicine)&#xD;
&#xD;
         11. Presence or history of gastrointestinal bleeding within the past 1 year.&#xD;
&#xD;
         12. Subjects who have serious problem with cardiovascular, respiratory, endocrine, central&#xD;
             nervous or History of neurotic mental.&#xD;
&#xD;
         13. Active malignancy of any type(ex. lymphoma, multiple myeloma etc)&#xD;
&#xD;
         14. Use of any medication that will affect pain perception during the study period;&#xD;
             physical therapy, corticosteroids, NSAIDs, asprin, topical analgesics.&#xD;
&#xD;
         15. Use of glucosamine, chondroitin during the study period.&#xD;
&#xD;
         16. Change of concomitant dose/use within 4 weeks.&#xD;
&#xD;
         17. Known allergy or hypersensitivity to medicine.&#xD;
&#xD;
         18. Subjects received hormone replacement therapy.&#xD;
&#xD;
         19. Use of any other investigational drug within 1 month prior to screening.&#xD;
&#xD;
         20. Investigators determines that it is not appropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Jae Cho, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung-Chul Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>We-Yeon Won, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoon-Jae Cho, MD</last_name>
    <email>yjcho@khmc.or.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>KyungHee University medical center</name>
      <address>
        <city>Seoul</city>
        <state>Hoegi-dong, Dongdaemun-gu</state>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yoon-Jae Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Medical Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Woncheon-dong Yeongtong-gu, Suwon</state>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>We-Yeon Won, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Yongon-dong, Chongno-gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Myung-Chul Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>August 12, 2013</last_update_submitted>
  <last_update_submitted_qc>August 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

